| Popis: |
Dilek Gogas Yavuz,1 Omar Akhtar,2 Kaywei Low,2 Adrien Gras,2 Batu Gurser,3 Esra Safak Yilmaz,4 Amaury Basse5 1School of Medicine, Marmara University, Section of Endocrinology and Metabolism, Istanbul, Turkey; 2Healthcare Market Access, Ipsos, Singapore; 3Novo Nordisk, İstanbul, Türkiye; 4Novo Nordisk, Ankara, Türkiye; 5Novo Nordisk, Novo Nordisk Region South East Europe, Middle East & Africa, Zurich, SwitzerlandCorrespondence: Amaury Basse, Email aayb@novonordisk.comBackground: Turkey currently has the highest obesity prevalence among its European counterparts. 32% and 61% of the population live with obesity and overweight, respectively. Overweight and obesity are linked to non-communicable diseases that incur incremental health and economic costs. The significant public health concern warrants an assessment of the cost of obesity.Methods: A micro-costing approach from the public payer perspective was conducted to estimate direct healthcare costs associated with ten obesity-related comorbidities (ORCs) in Turkey. Clinical practice guidelines and a systematic literature review informed ORCs and the respective cost categories. This was subsequently validated by a steering committee comprising seven experts. Seventy public sector physicians were surveyed to estimate healthcare resource use. Unit costs were derived from Social Security Institute’s Healthcare Implementation Communique. Cost items were summed to determine the annual cost per patient per ORC, which was validated by the steering committee. Medical inflation was considered in a scenario analysis that varied resource unit costs.Results: Chronic kidney disease, heart failure and type 2 diabetes are the costliest ORCs, incurring an annual cost of 28,600 TRY, 16,639 TRY and 11,993 TRY, respectively. Individuals in Turkey with any ORC triggered direct healthcare costs ranging 1857– 28,600 TRY annually. Costs were driven by tertiary care resources arising from treatment-related adverse events, disease complications and inpatient procedures. In the scenario analysis, medical resource unit costs were inflated by 18.7% and 39.4%, triggering an average increase in cost across all ORCs of 1998 TRY and 4210 TRY, respectively.Conclusion: Our findings confirm that obesity and its complications result in significant financial burden to the public healthcare system. By quantifying the burden of obesity across a comprehensive spectrum of ORCs, our study aims to support the economic case for investing in appropriate obesity interventions.Keywords: obesity, micro-costing, cost of illness, burden of illness, healthcare resource utilization |
